Diagnostic and therapeutic guideline for myeloproliferative neoplasm
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bang, Soo-Mee | - |
dc.contributor.author | Kim, Ho Young | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Kim, Hee-Jin | - |
dc.contributor.author | Won, Jong Ho | - |
dc.contributor.author | Kim, Bong Seog | - |
dc.contributor.author | Jung, Chul-Won | - |
dc.contributor.author | Chi, Hyun-Sook | - |
dc.date.accessioned | 2021-08-12T05:48:34Z | - |
dc.date.available | 2021-08-12T05:48:34Z | - |
dc.date.issued | 2011-01 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.issn | 2093-5951 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/16821 | - |
dc.description.abstract | The myeloproliferative neoplasm (MPN), polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (PMF) are clonal hematopoietic stem cell diseases that share in common overproduction of one or more of the formed elements of the blood with overlapping clinical features but exhibit different natural histories and different therapeutic requirements. Therefore, accuracy of diagnosis is the cornerstone of therapy. The World Health Organization diagnostic criteria for both the classic BCR-ABL-negative MPNs (that is PV, ET, and PMF) and chronic eosinophilic leukemia/hypereosinophilic syndrome have been revised in the 2008 edition, by incorporating new information on their V617F mutation in the Janus kinase 2 (JAK2) tyrosine kinase. The JAK2 V617F point mutation makes the normal hematopoietic progenitor cells hypersensitive to thrombopoietin, erythropoietin, and myeloid progenitor cells, leading to trilinear hematopoietic myeloproliferation. JAK2 V617F is found in most patients with PV, ET, or PMF and is, therefore, useful as a clonal marker when present. However their absence does not exclude the diagnosis of an MPN. The major complications of the MPN are thrombosis, hemorrhage and extramedullary hematopoiesis with massive splenomegaly and bone marrow failure. Myelofibrosis is classically listed as a complication of the MPN. Current treatment options are low dose aspirin, phlebotomy and cytoreductive therapy with hydroxyurea, anagrelide, and interferon for PV and ET but the most effective therapy is still bone marrow transplantation for PMF for the relief of symptoms and the prevention of complications. Drugs targeting JAK2 V617F are promising. This article reviews the changes in diagnostic criteria and algorithms, and also provides treatment guidelines that are tailored to routine clinical practice. | - |
dc.format.extent | 15 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.publisher | 대한의사협회 | - |
dc.title | Diagnostic and therapeutic guideline for myeloproliferative neoplasm | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5124/jkma.2011.54.1.112 | - |
dc.identifier.scopusid | 2-s2.0-79951477174 | - |
dc.identifier.wosid | 000286491300015 | - |
dc.identifier.bibliographicCitation | 대한의사협회지, v.54, no.1, pp 112 - 126 | - |
dc.citation.title | 대한의사협회지 | - |
dc.citation.volume | 54 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 112 | - |
dc.citation.endPage | 126 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001519423 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kciCandi | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | IDIOPATHIC HYPEREOSINOPHILIC SYNDROME | - |
dc.subject.keywordPlus | JAK2 EXON-12 MUTATIONS | - |
dc.subject.keywordPlus | VERA STUDY-GROUP | - |
dc.subject.keywordPlus | POLYCYTHEMIA-VERA | - |
dc.subject.keywordPlus | ESSENTIAL THROMBOCYTHEMIA | - |
dc.subject.keywordPlus | V617F MUTATION | - |
dc.subject.keywordPlus | MOLECULAR DIAGNOSTICS | - |
dc.subject.keywordPlus | JAK2(V617F) MUTATION | - |
dc.subject.keywordPlus | INTERFERON-ALPHA | - |
dc.subject.keywordPlus | OLMSTED COUNTY | - |
dc.subject.keywordAuthor | Myeloproliferative neoplasm | - |
dc.subject.keywordAuthor | Janus kinase 2V617F | - |
dc.subject.keywordAuthor | World Health Organization criteria | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.